Compare CORT & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | EHC |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.2B |
| IPO Year | 2001 | 1994 |
| Metric | CORT | EHC |
|---|---|---|
| Price | $113.05 | $122.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $96.50 | ★ $143.29 |
| AVG Volume (30 Days) | 805.4K | ★ 952.3K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ 24.22 |
| EPS | 0.09 | ★ 3.47 |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | $9.33 |
| Revenue Next Year | $26.98 | $8.14 |
| P/E Ratio | $1,259.44 | ★ $34.64 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $92.77 |
| 52 Week High | $126.38 | $127.99 |
| Indicator | CORT | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 59.64 |
| Support Level | $77.73 | $105.36 |
| Resistance Level | $122.21 | $127.50 |
| Average True Range (ATR) | 4.04 | 2.34 |
| MACD | -1.68 | -0.62 |
| Stochastic Oscillator | 15.22 | 42.47 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.